Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, September 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 223 articles:
HTML format


 

Single Articles

  1. ZHANG J, Li Z
    Diagnostic accuracy of MUC7 expression for bladder cancer: A systematic review and meta-analysis.
    Medicine (Baltimore). 2023;102:e34828.
    PubMed    
    Abstract available

  2. CHICK J, Alexander S, Herbert T, Huddart R, et al
    Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy.
    Phys Imaging Radiat Oncol. 2023;27:100481.
    PubMed    
    Abstract available

  3. MA X, Wei X, Yang G, Li S, et al
    A novel Natural killer cell-related gene signature for improving the prediction of prognosis and immunotherapy response in bladder cancer.
    Comb Chem High Throughput Screen. 2023.
    PubMed    
    Abstract available

  4. CUI Y, Yu L, Ma G, Wu J, et al
    Construction of enhanced CT radiomics model for noninvasive prediction of CXCL13's expression and immune infiltrates in bladder cancer based on logistic regression and support vector machine algorithm.
    Asian J Surg. 2023 Aug 29:S1015-9584(23)01299.
    PubMed    


  5. HOU L, Li H, Dong Q
    Clinical experience of modified percutaneous ureterostomy in bladder cancer patients receiving radical cystectomy.
    Asian J Surg. 2023 Aug 29:S1015-9584(23)01281.
    PubMed    


  6. NOH JI, Ahn EJ, Noh MG, Moon KS, et al
    Orthotopic Mouse Models of Urinary Bladder Cancer.
    In Vivo. 2023;37:2039-2043.
    PubMed    
    Abstract available

  7. LI H, Wang L, Li H, Zheng P, et al
    Analysis of risk factors for recurrence after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer: 2-year follow-up outcomes.
    Oncology. 2023 Aug 30. doi: 10.1159/000533410.
    PubMed    
    Abstract available

  8. LIU X, Qiu Z, Zhang X, Su Z, et al
    Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
    Environ Toxicol. 2023 Aug 30. doi: 10.1002/tox.23949.
    PubMed    
    Abstract available

  9. PLAMBECK BD, Tazegul TE, McElree IM, Steinberg RL, et al
    Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS.
    Urol Case Rep. 2023;50:102516.
    PubMed    
    Abstract available

  10. ZHANG D, Yin G, Zheng S, Chen Q, et al
    Construction of a prediction model for prognosis of bladder cancer based on the expression of ion channel-related genes.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:499-509.
    PubMed    
    Abstract available

  11. SAKAI D, Hirami Y, Sugita S, Maeda A, et al
    A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA.
    Retin Cases Brief Rep. 2023;17:630-634.
    PubMed    
    Abstract available

  12. LIU L, Sun FZ, Zhang PY, Xiao Y, et al
    Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature.
    Aging Male. 2023;26:2252102.
    PubMed    
    Abstract available

  13. HENDRI AZ, Soerohardjo I, Heriyanto DS, Khalilullah SA, et al
    Prognostic Significance of PD-L2 Expression in Association with Neutrophil-to-Lymphocyte Ratio in Urothelial Carcinoma of the Bladder.
    Asian Pac J Cancer Prev. 2023;24:2673-2679.
    PubMed    
    Abstract available

  14. SU X, Dong C, Liao W, Liu W, et al
    Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
    World J Surg Oncol. 2023;21:271.
    PubMed    
    Abstract available

  15. MOON S, Pandya V, McDonald A, Basu A, et al
    Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy.
    Urol Oncol. 2023 Aug 26:S1078-1439(23)00264.
    PubMed    
    Abstract available

  16. MARIOTTI A, Spatafora P, Sessa F, Saieva C, et al
    Gender and cystectomy for bladder cancer: A high-volume tertiary urologic care center experience.
    Eur J Surg Oncol. 2023;49:107034.
    PubMed    
    Abstract available

  17. ZHANG Y, Chen Y, Wen W
    Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.
    Front Immunol. 2023;14:1152806.
    PubMed    
    Abstract available

  18. HUANG LK, Lin YC, Chuang HH, Chuang CK, et al
    Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor.
    Front Oncol. 2023;13:1180888.
    PubMed    
    Abstract available

  19. JIA X, Zhang D, Zhou C, Yan Z, et al
    Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
    Front Oncol. 2023;13:1175183.
    PubMed    
    Abstract available

  20. CHAN K, Hampson A, Hayes J, Rabinowitz J, et al
    Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study.
    BJUI Compass. 2023;4:568-574.
    PubMed    
    Abstract available

  21. ZNAIDER VK, Mikkelsen LH, Jensen CFS, Sonksen J, et al
    Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
    Scand J Urol. 2023;58:52-59.
    PubMed    
    Abstract available

  22. WONG K, Abascal F, Ludwig L, Aupperle-Lellbach H, et al
    Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer.
    Genome Biol. 2023;24:191.
    PubMed    
    Abstract available

  23. ALFANO M, Alchera E, Sacchi A, Gori A, et al
    A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on alpha5beta1-targeted gold nanorods.
    J Nanobiotechnology. 2023;21:301.
    PubMed    
    Abstract available

  24. DEVLIES W, de Jong JJ, Hofmann F, Bruins HM, et al
    The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria: A Systematic Review from the European Association of Urology Guidelines Office.
    Eur Urol Focus. 2023 Aug 24:S2405-4569(23)00184.
    PubMed    
    Abstract available

  25. WANG W, Wang K, Qiu J, Li W, et al
    MRI-based radiomics analysis of bladder cancer: prediction of pathological grade and histological variant.
    Clin Radiol. 2023 Aug 12:S0009-9260(23)00327-6. doi: 10.1016/j.crad.2023.
    PubMed    
    Abstract available

  26. LALANI AA
    How I Do It: Maintenance avelumab.
    Can J Urol. 2023;30:11633-11638.
    PubMed    
    Abstract available

  27. TAN Z, Fu S, Zuo J, Wang J, et al
    Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  28. YOO D, Min KW, Pyo JS, Kim NY, et al
    Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma.
    Medicina (Kaunas). 2023;59:1452.
    PubMed    
    Abstract available

  29. RADIC SAVIC Z, Coric V, Vidovic S, Vidovic V, et al
    GPX3 rs8177412 Polymorphism Modifies Risk of Upper Urothelial Tumors in Patients with Balkan Endemic Nephropathy.
    Medicina (Kaunas). 2023;59:1421.
    PubMed    
    Abstract available

  30. CLAPS F, Pavan N, Ongaro L, Tierno D, et al
    BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.
    Int J Mol Sci. 2023;24:12596.
    PubMed    
    Abstract available

  31. CHIN FW, Chan SC, Veerakumarasivam A
    Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer.
    Diagnostics (Basel). 2023;13:2641.
    PubMed    
    Abstract available

  32. CHIN FW, Hussin H, Chau DM, Ong TA, et al
    Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression.
    Diagnostics (Basel). 2023;13:2636.
    PubMed    
    Abstract available

  33. KOUKOURIKIS P, Papaioannou M, Georgopoulos P, Apostolidis I, et al
    A Study of DNA Methylation of Bladder Cancer Biomarkers in the Urine of Patients with Neurogenic Lower Urinary Tract Dysfunction.
    Biology (Basel). 2023;12:1126.
    PubMed    
    Abstract available

  34. WALZ S, Pollehne P, Vollmer P, Aicher WK, et al
    Effects of Scaffolds on Urine- and Urothelial Carcinoma Tissue-Derived Organoids from Bladder Cancer Patients.
    Cells. 2023;12:2108.
    PubMed    
    Abstract available

  35. WANG D, Qiu Z, Wu C
    Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer.
    World J Surg Oncol. 2023;21:267.
    PubMed    
    Abstract available

  36. SHAO F, Jin K, Li B, Liu Z, et al
    Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
    Urol Oncol. 2023 Aug 23:S1078-1439(23)00254.
    PubMed    
    Abstract available

  37. LI S, Pan M, Wu X, Bai Y, et al
    miR-152-3p Inhibits Proliferation, Invasion and Autophagy in UMUC3 and TCCSUP Bladder Cancer Cell Lines via Suppressing HMGA2 Expression.
    Ann Clin Lab Sci. 2023;53:607-618.
    PubMed    
    Abstract available

  38. LUO Q, Huang C, Chen M
    Comprehensive analysis of N1-methylandenosine regulators and m1A-related mRNAs and lncRNAs as prognostic factors in bladder cancer.
    Gene. 2023 Aug 23:147735. doi: 10.1016/j.gene.2023.147735.
    PubMed    
    Abstract available

  39. MINAMI T, Inoue M, Yamaji T, Iwasaki M, et al
    Reproductive factors in the risk of bladder cancer and upper urinary tract cancer: The Japan Public Health Center-based Prospective Study.
    Cancer Epidemiol Biomarkers Prev. 2023 Aug 25:EPI-23-0201.
    PubMed    
    Abstract available

  40. HUI G, Stefanoudakis D, Zektser Y, Isaacs DJ, et al
    Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
    Curr Oncol. 2023;30:7398-7411.
    PubMed    
    Abstract available

  41. MAO C, Xu N
    Single-cell sequencing data reveals aggressive CD68-type macrophages and prognostic models in bladder cancer.
    Curr Med Chem. 2023 Aug 24. doi: 10.2174/0929867331666230824093312.
    PubMed    
    Abstract available

  42. WU X, Xu L, Li X, Zhou Y, et al
    A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway.
    Cell Death Dis. 2023;14:550.
    PubMed    
    Abstract available

  43. PETTIT MS, Crowder SL, Ackerman RS, Hafez O, et al
    Preoperative Nutritional Status and Enhanced Recovery after Surgery (ERAS) Prior to Radical Cystectomy: A Review of the Literature.
    Nutr Cancer. 2023;75:1743-1751.
    PubMed    
    Abstract available

  44. SCHWARZOVA L, Varchulova Novakova Z, Danisovic L, Ziaran S, et al
    Molecular classification of urothelial bladder carcinoma.
    Mol Biol Rep. 2023;50:7867-7877.
    PubMed    
    Abstract available

  45. TUDERTI G, Mastroianni R, Chiacchio G, Anceschi U, et al
    Long-term oncologic and functional outcomes following robot-assisted radical cystectomy and intracorporeal Padua ileal bladder: results from a single high-volume center.
    World J Urol. 2023;41:2359-2366.
    PubMed    
    Abstract available

  46. FERREIRO-PANTIN M, Anido-Herranz U, Betancor YZ, Cebey-Lopez V, et al
    Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
    ESMO Open. 2023;8:101611.
    PubMed    
    Abstract available

  47. LEBRET T, Paoletti X, Pignot G, Roumiguie M, et al
    Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.
    World J Urol. 2023;41:2381-2388.
    PubMed    
    Abstract available

  48. BAHLBURG H, Schuster F, Tully KH, Butea-Bocu MC, et al
    Prospective evaluation of functional outcomes in 395 patients with an ileal neobladder 1 year after radical cystectomy.
    World J Urol. 2023;41:2367-2374.
    PubMed    
    Abstract available

  49. CHO BC, Penkov K, Bondarenko I, Kurochkin A, et al
    A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
    ESMO Open. 2023;8:101589.
    PubMed    
    Abstract available

  50. KIM M, Lee JL, Shin SJ, Bae WK, et al
    Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
    ESMO Open. 2023;8:101588.
    PubMed    
    Abstract available

  51. LUO Z, Jiao B, Huang T, Zhao H, et al
    Development and external validation of a novel nomogram to predict intravesical recurrence after radical nephroureterectomy: a multicenter study.
    J Cancer Res Clin Oncol. 2023;149:11223-11231.
    PubMed    
    Abstract available

  52. SONG J, Sun X, Wang T, Yan L, et al
    Construction and validation of a cuproptosis-related lncRNA prognosis signature in bladder carcinoma.
    J Cancer Res Clin Oncol. 2023;149:11207-11221.
    PubMed    
    Abstract available

  53. WU M, Pang Y, Zheng X, Zhao J, et al
    Camrelizumab as adjuvant therapy in urothelial carcinomas after radical surgery in people living with HIV.
    Int J STD AIDS. 2023;34:720-727.
    PubMed    
    Abstract available

  54. KOVACS SA, Fekete JT, Gyorffy B
    Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
    Acta Pharmacol Sin. 2023;44:1879-1889.
    PubMed    
    Abstract available

  55. SANCHEZ CANOVAS M, Fernandez Garay D, Adoamnei E, Guirao Garcia E, et al
    Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
    Clin Transl Oncol. 2023;25:3021-3031.
    PubMed    
    Abstract available

  56. ZWAKENBERG MA, Westra JM, Halmos GB, Wedman J, et al
    Narrow-Band Imaging in Transoral Laser Surgery for Early Glottic Cancer: A Randomized Controlled Trial.
    Otolaryngol Head Neck Surg. 2023;169:606-614.
    PubMed    
    Abstract available

  57. SU C, Xue J, Liu N
    Cox Regression Analysis of Prognostic Factors of Intensity-Modulated Radiotherapy in Patients with Bladder Cancer.
    Arch Esp Urol. 2023;76:411-417.
    PubMed    
    Abstract available

  58. YU Q, Lan T, Ma Z, Wang Z, et al
    Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.
    Transl Androl Urol. 2023;12:1296-1307.
    PubMed    
    Abstract available

  59. SUNG WW
    Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In pres
    Eur Urol Oncol. 2023 Sep 5:S2588-9311(23)00171-2. doi: 10.1016/j.euo.2023.
    PubMed    


  60. CATTO JW, North B, Goff M, Carter A, et al
    Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk.
    BMJ Open. 2023;13:e076612.
    PubMed    
    Abstract available

  61. HWANG TJ, Davies BJ, Preston MA
    Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer.
    JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3304.
    PubMed    


  62. LIU X, Chen C, Xu P, Chen B, et al
    Development and experimental validation of a folate metabolism-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Funct Integr Genomics. 2023;23:291.
    PubMed    
    Abstract available

  63. LI B, Li X
    A preliminary study on the establishment of a cyst and cystic neoplasm tissue-mimicking model.
    J Cancer Res Ther. 2023;19:988-994.
    PubMed    
    Abstract available

  64. ZHENG J, Liu F, Zhang K, Xiang Y, et al
    High-power green-light laser endoscopic submucosal dissection for non-muscle-invasive bladder cancer: A technical improvement and its initial application.
    J Cancer Res Ther. 2023;19:945-950.
    PubMed    
    Abstract available

  65. BENJAMIN DJ, Hsu R
    Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Front Immunol. 2023;14:1258388.
    PubMed    
    Abstract available

  66. WANG J, Xiao Y, Yu Q, Zhang C, et al
    HSD17B1 could serve as a prognostic biomarker for bladder cancer patients.
    Asian J Surg. 2023 Sep 4:S1015-9584(23)01094.
    PubMed    


  67. RODEL C
    [Radical cystectomy or trimodal therapy for bladder cancer: where do we stand?].
    Urologie. 2023 Sep 5. doi: 10.1007/s00120-023-02194.
    PubMed    


  68. NIE Z, Guo N, Peng Y, Gao Y, et al
    Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.
    Sci Rep. 2023;13:14595.
    PubMed    
    Abstract available

  69. MA Z, Li Z, Mao Y, Ye J, et al
    AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer.
    Nat Commun. 2023;14:5415.
    PubMed    
    Abstract available

  70. REN C, Wang Q, Xu Z, Pan Y, et al
    Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.
    J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05352.
    PubMed    
    Abstract available

  71. SONG Y, Xu T
    Letter to the editor for the article "Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes".
    World J Urol. 2023 Sep 5. doi: 10.1007/s00345-023-04575.
    PubMed    


  72. KIM GH, Yuk HD, Jeong CW, Kwak C, et al
    Renal function change after radical cystectomy for urothelial carcinoma patients with a solitary kidney may be independent of urinary diversion type.
    Investig Clin Urol. 2023;64:457-465.
    PubMed    
    Abstract available

  73. CHAAYA C, Zgheib G, El Karak F
    Pharmacotherapy developments in Autophagy inhibitors for bladder cancer.
    Expert Opin Pharmacother. 2023 Sep 5. doi: 10.1080/14656566.2023.2254697.
    PubMed    
    Abstract available

  74. OKA S, Sakaguchi K, Hayashida M, Ito S, et al
    First case report of robot-assisted radical cystectomy for bladder cancer that developed after salvage radiotherapy following radical prostatectomy for prostate cancer.
    IJU Case Rep. 2023;6:310-313.
    PubMed    
    Abstract available

  75. LARIZADEH MH, Arabnejad F, Ebadzadeh MR
    Sequential Chemotherapy Followed by Radiotherapy Versus Concurrent Chemo-Radiation in Muscle Invasive Bladder Cancer.
    Urol J. 2023 Jul 31. doi: 10.22037/uj.v20i.7525.
    PubMed    
    Abstract available

  76. DOSHI B, Athans SR, Woloszynska A
    Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions.
    Oncogenesis. 2023;12:44.
    PubMed    
    Abstract available

  77. FAN YW, Lu IC, Hsu MY, Kuo WT, et al
    Synthetic lethality in human bladder cancer cells by curcumin via concurrent Aurora A inhibition and autophagy induction.
    J Nutr Biochem. 2023 Sep 2:109438. doi: 10.1016/j.jnutbio.2023.109438.
    PubMed    
    Abstract available

  78. SAHIB AS, Fawzi A, Zabibah RS, Koka NA, et al
    miRNA/epithelial-mesenchymal axis (EMT) axis as a key player in cancer progression and metastasis: A focus on gastric and bladder cancers.
    Cell Signal. 2023 Sep 2:110881. doi: 10.1016/j.cellsig.2023.110881.
    PubMed    
    Abstract available

  79. LI S, Ruan B, Wang Z, Xia J, et al
    Glucose dysregulation promotes oncogenesis in human bladder cancer by regulating autophagy and YAP1/TAZ expression.
    J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17943.
    PubMed    
    Abstract available

  80. LIU Y, Fan M, Xian S, Hu P, et al
    RBP7 Regulated by EBF1 Affects Th2 Cells and the Oocyte Meiosis Pathway in Bone Metastases of Bladder Urothelial Carcinoma.
    Front Biosci (Landmark Ed). 2023;28:189.
    PubMed    
    Abstract available

  81. WU Z, Li X, Gu Z, Xia X, et al
    Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer.
    Front Oncol. 2023;13:1102518.
    PubMed    
    Abstract available

  82. LIU J, Yang TY, Dai LQ, Shi K, et al
    Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer.
    Bioact Mater. 2023;31:315-332.
    PubMed    
    Abstract available

  83. DING Z, Jiao B, Chen X, Chen X, et al
    The function of Foxp1 represses beta-adrenergic receptor transcription in the occurrence and development of bladder cancer through STAT3 activity.
    Open Med (Wars). 2023;18:20230647.
    PubMed    
    Abstract available

  84. FENG H, Deng Z, Huang Y, Liu Z, et al
    A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder.
    Front Immunol. 2023;14:1219209.
    PubMed    
    Abstract available

  85. BAMIAS A, Stenzl A, Zagouri F, Andrikopoulou A, et al
    Defining Oligometastatic Bladder Cancer: A Systematic Review.
    Eur Urol Open Sci. 2023;55:28-37.
    PubMed    
    Abstract available

  86. FENG Y, Hao Y, Wang Y, Song W, et al
    Ultrasound Molecular Imaging of Bladder Cancer via Extradomain B Fibronectin-Targeted Biosynthetic GVs.
    Int J Nanomedicine. 2023;18:4871-4884.
    PubMed    
    Abstract available

  87. TATE T, Plumber SA, Al-Ahmadie H, Chen X, et al
    Combined Mek inhibition and Pparg activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced Carcinogenesis.
    bioRxiv. 2023 Aug 21:2023.08.19.553961. doi: 10.1101/2023.08.19.553961.
    PubMed    
    Abstract available

  88. LI K, Raveendran A, Xie G, Zhang Y, et al
    Prediction for recurrent non-muscle invasive bladder cancer.
    Cancer Biomark. 2023 Aug 15. doi: 10.3233/CBM-220373.
    PubMed    
    Abstract available

  89. ZONG R, Ma X, Shi Y, Geng L, et al
    The assessment of pathological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with DCE-MRI and DWI: a systematic review and meta-analysis.
    Br J Radiol. 2023 Sep 3:20230239. doi: 10.1259/bjr.20230239.
    PubMed    
    Abstract available

  90. GREBOWSKI R, Saluk J, Bijak M, Szemraj J, et al
    The role of SOD2 and NOS2 genes in the molecular aspect of bladder cancer pathophysiology.
    Sci Rep. 2023;13:14491.
    PubMed    
    Abstract available

  91. ANTHONY R, Rajandram R, Yap NY, Mun KS, et al
    Demethylases of H3 lysine 27 (H3K27) expression in urothelial carcinoma (UC) of the urinary bladder.
    Malays J Pathol. 2023;45:261-269.
    PubMed    
    Abstract available

  92. NAWAF C, Shiang A, Chauhan PS, Chaudhuri AA, et al
    Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials.
    Transl Oncol. 2023;37:101763.
    PubMed    
    Abstract available

  93. ARAD U, Werren C, White D
    Paraneoplastic sacroiliitis.
    BMJ Case Rep. 2023;16:e252572.
    PubMed    
    Abstract available

  94. ZANG J, Zhang R, Jin D, Xie F, et al
    Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
    J Pathol. 2023;261:198-209.
    PubMed    
    Abstract available

  95. KUJDOWICZ M, Perez-Guaita D, Chlosta P, Okon K, et al
    Fourier transform IR imaging of primary tumors predicts lymph node metastasis of bladder carcinoma.
    Biochim Biophys Acta Mol Basis Dis. 2023;1869:166840.
    PubMed    
    Abstract available

  96. TAOKA R, Yamada K, Sawanobori Y, Honda T, et al
    Oral 5-aminolevulinic acid administration before transurethral resection of bladder tumor induces perioperative nausea and vomiting.
    Photodiagnosis Photodyn Ther. 2023;43:103707.
    PubMed    
    Abstract available

  97. LI H, Chen J, Li Z, Chen M, et al
    S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8(+) T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma.
    Adv Sci (Weinh). 2023;10:e2300110.
    PubMed    
    Abstract available

  98. FACCHINETTI F, Hollebecque A, Braye F, Vasseur D, et al
    Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
    Cancer Discov. 2023;13:1998-2011.
    PubMed    
    Abstract available

  99. BABOUDJIAN M, Territo A, Gallioli A, Verri P, et al
    Long-Term Oncologic Outcomes of Endoscopic Management of High-Risk Upper Tract Urothelial Carcinoma: The Fundacio Puigvert's Experience.
    J Endourol. 2023;37:973-977.
    PubMed    
    Abstract available

  100. KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
    Dual immunocytochemical staining of annexin A10 and p53 in low-grade and papillary urothelial carcinoma contributes to improvement of diagnostic accuracy in urine cytology.
    Cancer Cytopathol. 2023;131:548-560.
    PubMed    
    Abstract available

  101. POYRY E, Nykanen V, Pulkkinen J, Viljanen E, et al
    Atypical urothelial cells classified according to the Paris System for Reporting Urinary Cytology: A 2-year experience with histological correlation from a Finnish tertiary care center-low rate and high risk of malignancy.
    Cancer Cytopathol. 2023;131:574-580.
    PubMed    
    Abstract available

  102. LI P, Meng C, Peng L, Gan L, et al
    Perioperative comparison between robot-assisted and laparoscopic radical cystectomy: An update meta-analysis.
    Asian J Surg. 2023;46:3464-3479.
    PubMed    
    Abstract available

  103. MESNARD B, de Vergie S, Chelghaf I, Bouchot O, et al
    Robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma: Peri and postoperative outcomes.
    Actas Urol Esp (Engl Ed). 2023;47:441-449.
    PubMed    
    Abstract available

  104. PEREZ JH, Faba OR, Gaya Sopena JM, Palou Redorta J, et al
    An aid to a better understanding of the definitions of BCG failure provided by the European Urology Association.
    Actas Urol Esp (Engl Ed). 2023;47:395-397.
    PubMed    


  105. TEKE K, Avci IE, Cinar NB, Baynal EA, et al
    Immune-inflammatory-nutritional status predicts oncologic outcomes after radical cystectomy for urothelial carcinoma of bladder.
    Actas Urol Esp (Engl Ed). 2023;47:430-440.
    PubMed    
    Abstract available

  106. MEHMANDAR-OSKUIE A, Tohidfar M, Hajikhani B, Karimi F, et al
    Anticancer Effects of Cell-Free Culture Supernatant of Escherichia coli in Bladder Cancer Cell Line: New Insight into the Regulation of Inflammation.
    Gene. 2023 Sep 12:147795. doi: 10.1016/j.gene.2023.147795.
    PubMed    
    Abstract available

  107. DE ARAUJO SOUZA LC, Ribeiro EC, Pinto TDA, de Ulhoa Barbosa TMJ, et al
    Urothelial bladder cancer with cardiac metastasis: Literature review and case report.
    Int J Surg Case Rep. 2023;111:108630.
    PubMed    
    Abstract available

  108. SLUSARCZYK A
    ASO Author Reflections: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Sep 14. doi: 10.1245/s10434-023-14301.
    PubMed    


  109. YAO X, Xu Z, Duan C, Zhang Y, et al
    Role of human papillomavirus and associated viruses in bladder cancer: An updated review.
    J Med Virol. 2023;95:e29088.
    PubMed    
    Abstract available

  110. ZHANG P, Xie X, Li C, Zhang C, et al
    LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer.
    Cancer Med. 2023 Sep 14. doi: 10.1002/cam4.6542.
    PubMed    
    Abstract available

  111. MARTINI A, Tholomier C, Mokkapati S, Dinney CPN, et al
    Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval.
    Front Immunol. 2023;14:1260498.
    PubMed    
    Abstract available

  112. ZHENG R, Gao F, Mao Z, Xiao Y, et al
    LncRNA BCCE4 Genetically Enhances the PD-L1/PD-1 Interaction in Smoking-Related Bladder Cancer by Modulating miR-328-3p-USP18 Signaling.
    Adv Sci (Weinh). 2023 Sep 13:e2303473. doi: 10.1002/advs.202303473.
    PubMed    
    Abstract available

  113. YAO Z, Xu N, Shang G, Wang H, et al
    Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.
    Nat Commun. 2023;14:5670.
    PubMed    
    Abstract available

  114. LI L, Yang J, Peng D, Zhang Y, et al
    177Lu-FAP-2286 Therapy in a Case of Recurrent Bladder Cancer With Multiple Metastatic Lesions.
    Clin Nucl Med. 2023 Sep 13. doi: 10.1097/RLU.0000000000004865.
    PubMed    
    Abstract available

  115. DENG Y, Deng Y, Wang H, Xie H, et al
    Solitary Axillary Lymph Node Metastasis From Bladder Cancer Detected by FDG PET/CT.
    Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004827.
    PubMed    
    Abstract available

  116. MULLER G, Butea-Bocu MC, Beyer B, Tully KH, et al
    Prospective evaluation of return to work, health-related quality of life and psychosocial distress after radical cystectomy: 1-year follow-up in 230 employed German bladder cancer patients.
    World J Urol. 2023 Sep 13. doi: 10.1007/s00345-023-04570.
    PubMed    
    Abstract available

  117. ZENG Y, Lv C, Wan B, Gong B, et al
    The current landscape of m6A modification in urological cancers.
    PeerJ. 2023;11:e16023.
    PubMed    
    Abstract available

  118. ABDEL-HAFIZ HA, Kailasam Mani SK, Huang W, Gouin KH 3rd, et al
    Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional signatures with prognostic relevance.
    iScience. 2023;26:107703.
    PubMed    
    Abstract available

  119. ISLAM NU, Jehangir M, Parry AH, Nazir SS, et al
    Diagnostic performance of multiparametric MRI based Vesical Imaging-Reporting and Data System (VI-RADS) scoring in discriminating between non-muscle invasive and muscle invasive bladder cancer.
    Pol J Radiol. 2023;88:e356-e364.
    PubMed    
    Abstract available

  120. ZHANG ZG, Shi ZD, Dong JJ, Chen YA, et al
    Novel potential urinary biomarkers for effective diagnosis and prognostic evaluation of high-grade bladder cancer.
    Transl Cancer Res. 2023;12:1992-2007.
    PubMed    
    Abstract available

  121. ZHANG C, Kang Y, Miao P, Chang D, et al
    A novel genes-based signature with prognostic value and predictive ability to select patients responsive to Atezolizumab treatment in bladder cancer: an analysis on data from real-world studies.
    Transl Cancer Res. 2023;12:2063-2070.
    PubMed    
    Abstract available

  122. LI W, Xiong Y, Zhu J, Jin X, et al
    Establishing a prognostic model with ferroptosis-related long non-coding RNAs in bladder cancer.
    Transl Cancer Res. 2023;12:2023-2032.
    PubMed    
    Abstract available

  123. TOPP BG, Channavazzala M, Mayawala K, De Alwis DP, et al
    Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
    Cancer Cell. 2023;41:1680-1688.
    PubMed    
    Abstract available

  124. SONG Y, Xu T
    Letter to the editor for the article "5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (alpha-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data".
    World J Urol. 2023 Sep 12. doi: 10.1007/s00345-023-04607.
    PubMed    


  125. QIN Y, Zu X, Li Y, Han Y, et al
    A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer.
    iScience. 2023;26:107722.
    PubMed    
    Abstract available

  126. HAN C, Wang J, Chen YL, Guan CP, et al
    The role of Bacillus Calmette-Guerin administration on the risk of dementia in bladder cancer patients: a systematic review and meta-analysis.
    Front Aging Neurosci. 2023;15:1243588.
    PubMed    
    Abstract available

  127. TREHAN D, Kumari R, Sharma J, Satuluri SH, et al
    Inhibition of protein kinase C isozymes causes immune profile alteration and possibly decreased tumorigenesis in bladder cancer.
    Am J Cancer Res. 2023;13:3832-3852.
    PubMed    
    Abstract available

  128. WANG X, Luo L, Xu J, Lu Q, et al
    Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/beta-catenin pathways.
    Genes Dis. 2023;11:1050-1065.
    PubMed    
    Abstract available

  129. WANG W, Zhang X, Jiang S, Xu P, et al
    A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
    Front Immunol. 2023;14:1187286.
    PubMed    
    Abstract available

  130. YANG F, Liu G, Wei J, Dong Y, et al
    Relationship between Bladder Cancer, Nutritional Supply, and Treatment Strategies: A Comprehensive Review.
    Nutrients. 2023;15:3812.
    PubMed    
    Abstract available

  131. PURNOMO AF, Daryanto B, Seputra KP, Budaya TN, et al
    Methylenetetrahydrofolate Reductase C677T (rs1801133) Polymorphism Is Associated with Bladder Cancer in Asian Population: Epigenetic Meta-Analysis as Precision Medicine Approach.
    Cancers (Basel). 2023;15:4402.
    PubMed    
    Abstract available

  132. SUN D, Hadjiiski L, Gormley J, Chan HP, et al
    Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on Clinical, Radiomics, and Deep-Learning Descriptors.
    Cancers (Basel). 2023;15:4372.
    PubMed    
    Abstract available

  133. YAO Q, Jiang H, Niu H, Hu G, et al
    Rotatable Bi-Channel En Bloc Resection of Bladder Tumor for Non-Muscle-Invasive Bladder Cancer in an Ex Vivo Porcine Model.
    Cancers (Basel). 2023;15:4255.
    PubMed    
    Abstract available

  134. KARIMI M, Mendez-Pineda S, Blanche H, Boland A, et al
    A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort.
    Cancers (Basel). 2023;15:4218.
    PubMed    
    Abstract available

  135. REYNOLDS T, Gordon M, Monar GVF, Moon D, et al
    Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for Bladder Cancer Detection.
    Int J Mol Sci. 2023;24:13651.
    PubMed    
    Abstract available

  136. XIE B, Lin J, Chen X, Zhou X, et al
    CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer.
    Mol Cancer. 2023;22:151.
    PubMed    
    Abstract available

  137. YU QX, Wang JC, Liu JF, Ye LX, et al
    Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer.
    Sci Rep. 2023;13:14803.
    PubMed    
    Abstract available

  138. WANG J, Xiao Y, Wu R, Zhang C, et al
    TGM1 could predict overall survival for patients with bladder cancer.
    Asian J Surg. 2023 Sep 6:S1015-9584(23)01104.
    PubMed    


  139. HMAIDY O, Jamal BR, Mayo M, Haidar M, et al
    Non-muscle invasive urothelial bladder cancer in a 17-year-old male: A rare case report.
    Int J Surg Case Rep. 2023;110:108728.
    PubMed    
    Abstract available

  140. WALZ S, Pollehne P, Geng R, Schneider J, et al
    A Protocol for Organoids from the Urine of Bladder Cancer Patients.
    Cells. 2023;12:2188.
    PubMed    
    Abstract available

  141. LAPUENTE M, Conway D, Wood LS, Kehoe K, et al
    Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
    Clin J Oncol Nurs. 2023;27:71-80.
    PubMed    
    Abstract available

  142. MANSINHO A, Cruz A, Marconi L, Pinto C, et al
    Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Adv Ther. 2023;40:4134-4150.
    PubMed    
    Abstract available

  143. KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
    Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and possible application in urine cytology.
    Pathol Int. 2023;73:444-455.
    PubMed    
    Abstract available

  144. LI J, Zhang H, Wu J, Li L, et al
    Granzymes expression patterns predict immunotherapy response and identify the heterogeneity of CD8+ T cell subsets.
    Cancer Biomark. 2023;38:77-102.
    PubMed    
    Abstract available

  145. MAYER M, Nachtsheim L, Prinz J, Shabli S, et al
    Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.
    Clin Exp Metastasis. 2023;40:395-405.
    PubMed    
    Abstract available

  146. LI J, Liu X
    Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression.
    Chem Biol Drug Des. 2023;102:805-814.
    PubMed    
    Abstract available

  147. BILEN MA, Robinson SB, Schroeder A, Peng J, et al
    Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
    Oncologist. 2023;28:790-798.
    PubMed    
    Abstract available

  148. MIAO S, He Q, Zhang Y, Wang L, et al
    Management of urinary incontinence after radical cystectomy and orthotopic neobladder: A scoping review of international practices.
    Nurs Open. 2023;10:6618-6634.
    PubMed    
    Abstract available

  149. ROCCO B, Sighinolfi MC, Sarchi L, Assumma S, et al
    First case of robot-assisted radical cystectomy and intracorporeal neobladder reconstruction with the Hugo RAS system: step-by-step surgical setup and technique.
    J Robot Surg. 2023;17:2247-2251.
    PubMed    
    Abstract available

  150. KURITZA V, Pei S
    Zosteriform cutaneous metastases from urothelial carcinoma: Report of a rare case and literature review.
    J Cutan Pathol. 2023 May 29. doi: 10.1111/cup.14471.
    PubMed    
    Abstract available

  151. KAIMAKLIOTIS HZ, Tachibana I, Woldu S, Labbate C, et al
    The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:387.
    PubMed    
    Abstract available

  152. CHUA KJ, Patel HV, Srivastava A, Doppalapudi SK, et al
    Annual trends of cystectomy complications: A contemporary analysis of the NSQIP database.
    Urol Oncol. 2023;41:390.
    PubMed    
    Abstract available

  153. SOBHANI S, Alsyouf M, Ahmadi H, Ghoreifi A, et al
    Association between early postradical cystectomy kidney injury and perioperative outcome in enhanced recovery era.
    Urol Oncol. 2023;41:389.
    PubMed    
    Abstract available

  154. DAVARO F, Davaro E, Rose K, Murthy P, et al
    Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma.
    Urol Oncol. 2023;41:389.
    PubMed    
    Abstract available

  155. SANGOI AR, Akgul M, Williamson SR
    Artifactual Cystic Spaces in Prostatic Transurethral Resections and Related Specimens: A Potential Diagnostic Confounder.
    Int J Surg Pathol. 2023;31:1048-1056.
    PubMed    
    Abstract available

  156. LAI S, Liu J, Lai C, Seery S, et al
    Prognostic variations between "primary" and "progressive" muscle-invasive bladder cancer following radical cystectomy: A novel propensity score-based multicenter cohort study.
    Int J Surg. 2023 Sep 22. doi: 10.1097/JS9.0000000000000790.
    PubMed    
    Abstract available

  157. LOPEZ-BELTRAN A, Raspollini MR, Hansel D, Comperat E, et al
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer.
    Am J Surg Pathol. 2023 Sep 22. doi: 10.1097/PAS.0000000000002121.
    PubMed    
    Abstract available

  158. MALIK RF, Berry R, Lau BD, Busireddy KR, et al
    Systematic Evaluation of Imaging Features of Early Bladder Cancer Using Computed Tomography Performed before Pathologic Diagnosis.
    Tomography. 2023;9:1734-1744.
    PubMed    
    Abstract available

  159. AHMADIEH N, Zeidan T, Chebel JA, Haddad FG, et al
    Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in a Lebanese experience: in all aspects.
    Gulf J Oncolog. 2023;1:33-39.
    PubMed    
    Abstract available

  160. NAVARRO-DOMENECH I, Arulanantham S, Liu ZA, Tjong M, et al
    Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer.
    Radiat Oncol. 2023;18:154.
    PubMed    
    Abstract available

  161. COE C, Chirputkar K, Joseph L, Jude EB, et al
    Pedal acrometastasis secondary to urothelial carcinoma masquerading as Charcot arthropathy in a patient with diabetes.
    BMJ Case Rep. 2023;16:e254468.
    PubMed    
    Abstract available

  162. PISZCZEK R, Krajewski W, Subiela JD, Del Giudice F, et al
    Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guerin immunotherapy.
    Minerva Urol Nephrol. 2023;75:591-599.
    PubMed    
    Abstract available

  163. WANG S, Ge C
    Chronic Obstructive Pulmonary Disease Mortality in Bladder Cancer Patients: A SEER-Based Competing Risk Analysis.
    Urol J. 2023 Sep 17. doi: 10.22037/uj.v20i.7644.
    PubMed    
    Abstract available

  164. VAN DORP J, van der Heijden MS
    The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition.
    Front Immunol. 2023;14:1235884.
    PubMed    
    Abstract available

  165. HEISHIMA K, Sugito N, Abe C, Hirata A, et al
    Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model.
    Mol Ther Nucleic Acids. 2023;33:960-982.
    PubMed    
    Abstract available

  166. HUANG H, Liu A, Liang Y, Xin Y, et al
    A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
    BMC Med. 2023;21:357.
    PubMed    
    Abstract available

  167. GAO D, Wang R, Gong Y, Yu X, et al
    CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway.
    Free Radic Biol Med. 2023 Sep 17:S0891-5849(23)00641.
    PubMed    
    Abstract available

  168. SLUSARCZYK A, Zapala P, Zapala L, Borkowski T, et al
    ASO Visual Abstract: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer-A Population-Based Analysis.
    Ann Surg Oncol. 2023 Sep 19. doi: 10.1245/s10434-023-14286.
    PubMed    


  169. SONG H, Yang S, Yu B, Li N, et al
    CT-based deep learning radiomics nomogram for the prediction of pathological grade in bladder cancer: a multicenter study.
    Cancer Imaging. 2023;23:89.
    PubMed    
    Abstract available

  170. BREYER J, Eckstein M, Sikic D, Wezel F, et al
    Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
    Sci Rep. 2023;13:15437.
    PubMed    
    Abstract available

  171. MONDA S, Pratsinis M, Lui H, Noel O, et al
    Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery.
    Eur Urol Focus. 2023 Sep 16:S2405-4569(23)00199.
    PubMed    
    Abstract available

  172. CHEN Y, Zeng S, Jiao B, Zhang H, et al
    Adherence to the Diabetes Risk Reduction Diet and bladder cancer risk in the Prostate, Lung, Colorectal, Ovarian (PLCO) cohort.
    Cancer Epidemiol Biomarkers Prev. 2023.
    PubMed    
    Abstract available

  173. KADHUM T, Selinski S, Blaszkewicz M, Reinders J, et al
    Bladder cancer course, four genetic high-risk variants, and histopathological findings.
    EXCLI J. 2023;22:867-879.
    PubMed    
    Abstract available

  174. MA SY, An Y, Sun JX, Xu MY, et al
    The effect of different timing of blood transfusion on oncological outcomes of patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2023;13:1223592.
    PubMed    
    Abstract available

  175. FAHMY O, Kochergin M, Asimakopoulos AD, Gakis G, et al
    Practice change: No benefit of extended lymphadenectomy at radical cystectomy in patients with muscle invasive bladder cancer.
    Semin Oncol. 2023 Sep 14:S0093-7754(23)00064.
    PubMed    
    Abstract available

  176. DING Q, Tang W, Li X, Ding Y, et al
    Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer.
    J Control Release. 2023 Sep 15:S0168-3659(23)00611.
    PubMed    
    Abstract available

  177. BOLL LM, Perera-Bel J, Rodriguez-Vida A, Arpi O, et al
    The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
    Sci Rep. 2023;13:15287.
    PubMed    
    Abstract available

  178. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
    Urol Oncol. 2023 Sep 13:S1078-1439(23)00263.
    PubMed    
    Abstract available

  179. ZHANG Y, Rumgay H, Li M, Yu H, et al
    The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040.
    J Glob Health. 2023;13:04109.
    PubMed    
    Abstract available

  180. LUO P, Zheng L, Zou J, Chen T, et al
    Insights into vitamin A in bladder cancer, lack of attention to gut microbiota?
    Front Immunol. 2023;14:1252616.
    PubMed    
    Abstract available

  181. STOCKEM CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, et al
    Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
    Front Oncol. 2023;13:1246603.
    PubMed    
    Abstract available

  182. QU Y, Yao Z, Xu N, Shi G, et al
    Plasma proteomic profiling discovers molecular features associated with upper tract urothelial carcinoma.
    Cell Rep Med. 2023;4:101166.
    PubMed    
    Abstract available

  183. SOUKUP J, Manethova M, Stejskal V, Hornychova H, et al
    Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
    Endocr Pathol. 2023;34:333-341.
    PubMed    
    Abstract available

  184. ASERO V, Scornajenghi CM, Carino D, Pandolfo SD, et al
    Comment on: "Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy".
    Minerva Urol Nephrol. 2023;75:649-651.
    PubMed    


  185. LUO HL, Lee YC, Chang YL, Hsu WC, et al
    MicroRNA-145-5p suppresses cell proliferation, migration, and invasion in upper tract urothelial carcinoma by targeting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase.
    J Cell Biochem. 2023;124:1324-1345.
    PubMed    
    Abstract available

  186. HUANG W, Warrick JI, Chen G
    Clinical and pathological characteristics of metastatic tumors to the urinary bladder.
    Ann Diagn Pathol. 2023;66:152179.
    PubMed    
    Abstract available

  187. MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
    Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Anticancer Res. 2023;43:4055-4060.
    PubMed    
    Abstract available

  188. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    PubMed    
    Abstract available

  189. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
    Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
    BJU Int. 2023;132:428-434.
    PubMed    
    Abstract available

  190. LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
    Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
    Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
    PubMed    
    Abstract available

  191. JIANG D, Lan X, Cai W
    PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
    Clin Cancer Res. 2023;29:3259-3261.
    PubMed    
    Abstract available

  192. DUAN X, Xia L, Zhang Z, Ren Y, et al
    First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2023;29:3395-3407.
    PubMed    
    Abstract available

  193. SALARI K, Sundi D, Lee JJ, Wu S, et al
    Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
    Clin Cancer Res. 2023;29:3668-3680.
    PubMed    
    Abstract available

  194. ZLOTTA AR, Lajkosz K, Efstathiou JA
    Reply to Thomas Seisen, Morgan Roupret, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institut
    Eur Urol. 2023 Sep 1:S0302-2838(23)03066-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  195. SEISEN T, Roupret M, Blanchard P
    Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
    Eur Urol. 2023 Aug 31:S0302-2838(23)03065-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  196. INAMURA K
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Sep 9:S0302-2838(23)03085-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  197. STRANDGAARD T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, et al
    Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer.
    Eur Urol. 2023 Sep 15:S0302-2838(23)03014-2. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  198. KHETRAPAL P, Wong JKL, Tan WP, Rupasinghe T, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials.
    Eur Urol. 2023;84:393-405.
    PubMed    
    Abstract available

  199. YU EY, Tang QY, Chen YT, Zhang YX, et al
    Genome-wide exploration of genetic interactions for bladder cancer risk.
    Int J Cancer. 2023 Aug 28. doi: 10.1002/ijc.34690.
    PubMed    
    Abstract available

  200. SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al
    Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
    Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
    PubMed    
    Abstract available

  201. PRADHAN P, Jia G, Khankari NK, Zheng W, et al
    Evaluating interactions of polygenic risk scores and NAT2 genotypes with tobacco smoking in bladder cancer risk.
    Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34736.
    PubMed    
    Abstract available

  202. SZARVAS T
    Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
    PubMed    


  203. SATO T, Sano T, Kawamura S, Ikeda Y, et al
    Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
    PubMed    
    Abstract available

  204. KIKUCHI E, Hayakawa N
    Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
    Int J Urol. 2023;30:786-787.
    PubMed    


  205. HARA T, Furukawa J, Okamura Y, Bando Y, et al
    The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
    Int J Urol. 2023;30:779-786.
    PubMed    
    Abstract available

  206. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
    Int J Urol. 2023;30:738-745.
    PubMed    
    Abstract available

  207. ITO K, Kita Y, Kobayashi T
    Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:696-703.
    PubMed    
    Abstract available

  208. GOTO Y
    Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:704.
    PubMed    


  209. ASSEM A, Kassem A, Sherif M, Lotfi A, et al
    Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer.
    Int Urol Nephrol. 2023 Aug 28. doi: 10.1007/s11255-023-03752.
    PubMed    
    Abstract available

  210. YOU C, Li Q, Qing L, Li R, et al
    Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
    Int Urol Nephrol. 2023 Sep 2. doi: 10.1007/s11255-023-03765.
    PubMed    
    Abstract available

  211. KHALIFA SE
    Immunohistochemical expression of CD117/KIT, HER2, and Erbeta in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients.
    Int Urol Nephrol. 2023;55:2473-2481.
    PubMed    
    Abstract available

  212. SIEFKER-RADTKE AO, Cauley D, Alhalabi O
    Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:4084-4086.
    PubMed    


  213. JIAO H, Wang L, Zhou X, Wu J, et al
    Prognostic Ability of Nutritional Indices for Outcomes of Bladder Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2023 Aug 29:1-9. doi: 10.1159/000531884.
    PubMed    
    Abstract available

  214. CHEN Z
    The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through PTEN-Mediated AKT/mTOR Pathway.
    Urol Int. 2023 Sep 4:1-9. doi: 10.1159/000532128.
    PubMed    
    Abstract available

  215. STRUCK JP, Ozimek T, Schnoor M, Offermann A, et al
    The Role of Urine and Washing Cytology in Primary Transurethral Resection of Bladder Tumours.
    Urol Int. 2023;107:792-800.
    PubMed    
    Abstract available

  216. BOKARICA P, Alfirevic M, Hrkac A, Glas AM, et al
    Letter to the Editor regarding the Article "Postoperative Mortality Rate after Radical Cystectomy: A Systematic Review of Epidemiologic Series".
    Urol Int. 2023;107:839-840.
    PubMed    


  217. HYMAN MJ, Skolarus TA, Litwack K, Meltzer DO, et al
    Outcomes of Hematuria Evaluation by Advanced Practice Providers and Urologists.
    Urology. 2023;178:67-75.
    PubMed    
    Abstract available

  218. LYALL V, Aziz Ould Ismail A, Haggstrom DA, Issa MM, et al
    Accurate Documentation Contributes to Guideline-concordant Surveillance of Non-Muscle Invasive Bladder Cancer: a Multi-site VA Study.
    Urology. 2023 Sep 1:S0090-4295(23)00729-X. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  219. NABAVIZADEH R, Pessoa RR, Dumbrava MG, Packiam VT, et al
    Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A Contemporary Series.
    Urology. 2023 Sep 7:S0090-4295(23)00733-1. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  220. PENN T, Borza T, Liou JI, Jason Abel E, et al
    The Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes.
    Urology. 2023 Sep 18:S0090-4295(23)00794-X. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  221. NASR S, Haddad FG, Khazen J, Kattan J, et al
    PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
    BMC Cancer. 2023;23:817.
    PubMed    
    Abstract available

  222. TSAI TH, Su PJ, Huang SY, Kuo MC, et al
    The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2023;23:871.
    PubMed    
    Abstract available

  223. LEE J, Kim E, Park J, Choi S, et al
    Pre-analytical handling conditions and protein marker recovery from urine extracellular vesicles for bladder cancer diagnosis.
    PLoS One. 2023;18:e0291198.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;